In a significant development for Medicare patients, the Centers for Medicare & Medicaid Services (CMS) has announced a new program that will cover up to $500 worth of hemp-derived products for eligible beneficiaries. This initiative, which officially launched on April 1, 2026, has garnered attention from various stakeholders, including notable figures like Mehmet Oz, who have shown support for expanding healthcare options through alternative treatments.
The Medicare hemp coverage program primarily focuses on cannabidiol (CBD) products while also permitting a limited amount of tetrahydrocannabinol (THC) in these products. Specifically, the program allows for a maximum delta-9 THC percentage of 0.3 by dry weight and a total THC limit of 3 milligrams per serving. This careful regulation aims to ensure that patients can benefit from the therapeutic properties of hemp without experiencing psychoactive effects.
As the program unfolds, it has faced challenges, particularly from anti-cannabis organizations like Smart Approaches to Marijuana (SAM). The government has filed a brief asserting that these organizations lack standing to challenge the Medicare hemp coverage policy. Individual plaintiff David Evans, a Medicare recipient, claims he has standing but has been rejected by federal agencies, leading to a legal dispute that highlights the complexities surrounding cannabis-related healthcare initiatives.
Despite these challenges, the government maintains that the plaintiffs have not been harmed by the Medicare hemp program. In a recent ruling, Judge Trevor N. McFadden denied a request for a temporary restraining order to halt the program’s launch. This decision underscores the government’s commitment to moving forward with the initiative, which is designed as a voluntary component of existing models that allow willing providers to consult with consenting beneficiaries about eligible hemp products.
Importantly, CMS does not cover the cost of hemp products under the Beneficiary Engagement Incentive (BEI); instead, providers are expected to furnish eligible products at their own cost. The BEI operates within a shared-savings framework, which defines the underlying models for the program. This approach aims to encourage healthcare providers to explore innovative treatment options while ensuring that patients have access to beneficial products.
In the broader context, the Medicare hemp coverage program was introduced as part of an initiative to improve access to full-spectrum CBD products, following an executive order signed by former President Donald Trump. This move reflects a growing recognition of the potential benefits of hemp-derived products in managing various health conditions, including chronic pain and anxiety.
As the program gains traction, the White House Office of Management and Budget has been actively involved, holding meetings to discuss a Food and Drug Administration (FDA) enforcement policy regarding CBD products. The FDA has issued guidance indicating that it does not intend to interfere with the Medicare hemp-derived products coverage plan, further solidifying the program’s foundation.
Initial reactions to the Medicare hemp coverage program have been mixed. While some healthcare advocates, including Mehmet Oz, celebrate the expanded access to alternative treatments, others, like David Evans, express concerns about the implications of such a program. As the dialogue continues, it is clear that this initiative represents a significant step toward integrating hemp-derived products into mainstream healthcare, potentially transforming the landscape for Medicare beneficiaries seeking alternative therapies.
